(R)-toluene-4-sulfonic acid, 6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-yl-methyl ester | 1189115-69-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-toluene-4-sulfonic acid, 6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-yl-methyl ester
• 英文别名: (R)-toluene-4-sulfonic acid 6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-yl-methyl ester；(R)-toluene-4-sulfonic acid 6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester；toluene-4-sulfonic acid 6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl ester；[(2R)-6-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl 4-methylbenzenesulfonate
• CAS: 1189115-69-2
• 化学式: C₁₆H₁₅ClO₅S
• 分子量: 354.811
• InChiKey: FVZRTEIKEHQRIB-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-toluene-4-sulfonic acid, 6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-yl-methyl ester 、 potassium phtalimide 以 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-2-((6-chloro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methyl)isoindoline-1,3-dione
  参考文献：
  名称：

  PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES

  摘要：

  本发明涉及一种制备苯并杂环磺酰胺的方法，用于治疗癫痫和相关疾病。

  公开号：

  US20090247617A1
• 作为产物：
  描述：

  (S)-(6-chloro-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanol 、 对甲苯磺酰氯 在 N-甲基吗啉 、 4-二甲氨基吡啶 作用下， 以 四氢呋喃 、 正庚烷 、 二氯甲烷 为溶剂， 反应 240.0h， 生成 (R)-toluene-4-sulfonic acid, 6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-yl-methyl ester
  参考文献：
  名称：

  PROCESS FOR PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES

  摘要：

  本发明涉及用于制备苯并杂环衍生物的方法，用于治疗癫痫和相关疾病。本发明还涉及用于制备苯并杂环衍生物合成中间体的方法。

  公开号：

  US20090247618A1

文献信息

• [EN] PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES AND CRYSTALLINE FORM OF N- ( ( (2S) -6-CHLORO-2,3-DIHYDRO-L,4-BENZODIOXIN-2-YL) METHYL-SULFAMIDE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE SULFAMATES D'HÉTÉROARYLE CONDENSÉS AVEC UN BENZO ET FORME CRISTALLINE DE N-((2S)-6-CHLORO-2,3-DIHYDRO-L,4-BENZODIOXIN- 2-YL) MÉTHYLSULFAMIDE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009120191A1

  公开（公告）日：2009-10-01

  The present invention is directed to a process for the preparation of benzo-fused heteroaryl sulfamates, useful for the treatment of epilepsy and related disorders according to formula (IA) and to a crystalline compound of formula (I-S). Process for the preparation of a compound of formula (IA).

  本发明涉及一种制备苯并杂环磺酸酯的过程，该过程适用于治疗癫痫和相关疾病，其化学式为(IA)，以及化学式(I-S)的结晶化合物。化合物(IA)的制备过程。
• PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL SULFAMATES
  申请人：Abdel-Magid Ahmed F.

  公开号：US20090247617A1

  公开（公告）日：2009-10-01

  The present invention is directed to a process for the preparation of benzo-fused heteroaryl sulfamates, useful for the treatment of epilepsy and related disorders.

  本发明涉及一种制备苯并杂环磺酰胺的方法，用于治疗癫痫和相关疾病。
• Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Pharmacological Properties of (<i>S</i>)-<i>N</i>-[(6-Chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112)
  作者：David F. McComsey、Virginia L. Smith-Swintosky、Michael H. Parker、Douglas E. Brenneman、Ewa Malatynska、H. Steve White、Brian D. Klein、Karen S. Wilcox、Michael E. Milewski、Mark Herb、Michael F. A. Finley、Yi Liu、Mary Lou Lubin、Ning Qin、Allen B. Reitz、Bruce E. Maryanoff

  DOI：10.1021/jm400894u

  日期：2013.11.27

  Broad-spectrum anticonvulsants are of considerable interest as antiepileptic drugs, especially because of their potential for treating refractory patients. Such "neurostabilizers" have also been used to treat other neurological disorders, including migraine, bipolar disorder, and neuropathic pain. We synthesized a series of sulfamide derivatives (4-9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity. Thus, we identified promising sulfamide 4 (JNJ-26489112) and explored its pharmacological properties. Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, electrically induced, and chemically induced seizures. Mechanistically, 4 inhibited voltage-gated Na+ channels and N-type Ca2+ channels and was effective as a K+ channel opener. The anticonvulsant profile of 4 suggests that it may be useful for treating multiple forms of epilepsy (generalized tonic-clonic, complex partial, absence seizures), including refractory (or pharmacoresistant) epilepsy, at dose levels that confer a good safety margin. On the basis of its pharmacology and other favorable characteristics, 4 was advanced into human clinical studies.
• [EN] PROCESSES FOR THE PREPARATION OF BENZO-FUSED DIOXIN DERIVATIVES<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE DÉRIVÉS D'HÉTÉROARYLE BENZO-CONDENSÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009120192A3

  公开（公告）日：2010-01-21
• [EN] PROCESS FOR THE PREPARATION OF BENZO-FUSED HETEROARYL DERIVATIVES<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE DÉRIVÉS D'HÉTÉROARYLE BENZO-CONDENSÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009120192A2

  公开（公告）日：2009-10-01

  The present invention is directed to processes for the preparation of benzo-fused heteroaryl derivatives, useful for the treatment of epilepsy and related disorders. The present invention is further directed to processes for the preparation of intermediates in the synthesis of the benzo-fused heteroaryl derivatives.